NCT04998864 2026-04-16
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
InSightec
Completed
Clinical Trials
595 trialsNCT03213665 2026-04-13
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT04988750 2026-04-13
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
NaviFUS Corporation
Phase NA Completed
NCT04446416 2026-04-09
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
NCT03526250 2026-04-03
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03213678 2026-04-02
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT07499141 2026-03-30
UFGAG
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Completed
NCT02851706 2026-03-27
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
National Institutes of Health Clinical Center (CC)
Completed
NCT02286167 2026-03-24
GLAD
Wake Forest University Health Sciences
Phase NA Completed
NCT03251989 2026-03-24
Rare CNS Tumors Outcomes &Risk
National Institutes of Health Clinical Center (CC)
Completed
NCT03551249 2026-03-20
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
InSightec
Phase NA Completed
NCT02115074 2026-03-18
FLUVABREX
Centre Oscar Lambret
Phase 1 Completed
NCT05577416 2026-03-18
AB-218-IIT-201
Melbourne Health
Phase EARLY_PHASE1 Completed
NCT05393258 2026-03-17
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
Washington University School of Medicine
Phase NA Completed
NCT01165333 2026-03-16
CILENT
Centre Oscar Lambret
Phase 1 Completed
NCT03257618 2026-03-12
TEMOIN
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Completed
NCT02303678 2026-03-06
D2C7 for Adult Patients With Recurrent Malignant Glioma
Duke University
Phase 1 Completed
NCT04391595 2026-03-06
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Completed
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT05984667 2026-02-20
C-SMART
Virginia Commonwealth University
Completed
NCT07416838 2026-02-18
Quality of Life and Cognitive Functioning in Patients With Glial Tumors
Institute of Oncology Ljubljana
Phase NA Completed
NCT02073994 2026-02-17
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Servier
Phase 1 Completed
NCT02481154 2026-02-17
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Servier
Phase 1 Completed
NCT03343197 2026-02-17
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Servier
Phase 1 Completed
NCT03681028 2026-02-12
Feasibility of Individualized Therapy for Recurrent Glioblastoma
University of California, San Francisco
Phase 1 Completed
NCT07342699 2026-01-15
Location-Molecular Integrated Outcomes in 450 Cerebellar Glioma Microsurgical Cases
West China Hospital
Completed
NCT07343492 2026-01-15
fMRI Reveal Functional Preservation in Glioma Peritumoral Edema
West China Hospital
Completed
NCT04773782 2026-01-13
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
Phase 1/2 Completed
NCT04295759 2026-01-05
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Pediatric Brain Tumor Consortium
Phase 1 Completed
NCT06625047 2025-12-31
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
Mayo Clinic
Phase 4 Completed
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT02473380 2025-12-19
GLIOSPECT
Hospices Civils de Lyon
Phase 1 Completed
NCT06451042 2025-12-18
FET-TREAT
Sunnybrook Health Sciences Centre
Completed
NCT03638167 2025-12-17
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Seattle Children's Hospital
Phase 1 Completed
NCT03532295 2025-11-21
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
Phase 2 Completed
NCT03746080 2025-11-14
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Stanford University
Phase 2 Completed
NCT02162732 2025-11-03
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
Phase NA Completed
NCT03557359 2025-11-03
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
Phase 2 Completed
NCT04826393 2025-10-22
ASP8374 + Cemiplimab in Recurrent Glioma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01991977 2025-10-20
18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT06439420 2025-10-01
CBT-I in PBT
Virginia Commonwealth University
Phase 2 Completed
NCT03975959 2025-09-23
PROMESSE
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Completed
NCT05157594 2025-09-22
PROGLIO
Centre Jean Perrin
Completed
NCT03561870 2025-09-12
OLAGLI
Hospices Civils de Lyon
Phase 2 Completed
NCT03050736 2025-09-04
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT01165632 2025-09-02
Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT01478178 2025-08-29
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Kintara Therapeutics, Inc.
Phase 1/2 Completed
NCT02717962 2025-08-29
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT04388475 2025-08-12
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Oblato, Inc.
Phase 2 Completed